SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-23-066555
Filing Date
2023-08-14
Accepted
2023-08-14 09:05:20
Documents
14
Period of Report
2023-08-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea183293-8k_virpaxpharm.htm   iXBRL 8-K 26911
2 PRESS RELEASE ISSUED BY VIRPAX PHARMACEUTICALS, INC. DATED AUGUST 14, 2023 ea183293ex99-1_virpax.htm EX-99.1 77740
6 GRAPHIC ex99-1_001.jpg GRAPHIC 2319
  Complete submission text file 0001213900-23-066555.txt   294908

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE vrpx-20230814.xsd EX-101.SCH 3027
4 XBRL LABEL FILE vrpx-20230814_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE vrpx-20230814_pre.xml EX-101.PRE 22367
8 EXTRACTED XBRL INSTANCE DOCUMENT ea183293-8k_virpaxpharm_htm.xml XML 3420
Mailing Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312
Business Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-4597
Virpax Pharmaceuticals, Inc. (Filer) CIK: 0001708331 (see all company filings)

IRS No.: 821510982 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40064 | Film No.: 231166670
SIC: 2834 Pharmaceutical Preparations